Skip to main content
Cancer cell in concentric circle. Overcoming resistance in Cancer. Young woman with cancer smiling
Welcome to ORIC, where we’re targeting resistance mechanisms to improve patients’ lives.
Welcome to ORIC, where we’re targeting resistance mechanisms to improve patients’ lives.
i

Our bold vision is to discover, develop and commercialize innovative therapies that address cancer resistance, including by making existing therapies work better and longer.

Profound advancements in oncology drug development have expanded the treatment options available to patients, yet therapeutic resistance and relapse continue to limit the efficacy and duration of clinical benefit of such treatments. Cancer resistance continues to be one of the most daunting challenges facing patients, clinicians and researchers in oncology today. At ORIC, our resistance platform is focused on three areas:

1

Innate
resistance

Derives from an unaddressed oncogenic driver that promotes tumor growth
2

Acquired
resistance

The result of an induced or enriched oncogenic driver that arises in response to treatment
3

Bypass
resistance

The activation of a compensatory signaling pathway in response to treatment
Large cancer cell in circle with multiple cancer cells in background

Clinical trials now enrolling

We are currently enrolling three phase 1 studies, which include ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer. Do you qualify?

African american woman expressively talking with colleagues

Motivated by a shared purpose

Our collaborative, open culture gives each of us the authority, responsibility and support to do cutting-edge work on therapies for treatment-resistant cancers.